TWD 138.5
(-1.07%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 76.08 Million TWD | 839.02% |
2022 | 8.1 Million TWD | 46.4% |
2021 | 5.53 Million TWD | 3.03% |
2020 | 5.37 Million TWD | 3604.83% |
2019 | 145 Thousand TWD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 79.27 Million TWD | 4.19% |
2024 Q2 | 69.15 Million TWD | -12.78% |
2023 Q3 | 179.93 Million TWD | -0.09% |
2023 FY | 76.08 Million TWD | 839.02% |
2023 Q1 | 176.23 Million TWD | 0.0% |
2023 Q2 | 180.09 Million TWD | 2.19% |
2023 Q4 | 76.08 Million TWD | -57.71% |
2022 Q4 | - TWD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Allied Biotech Corporation | 910.11 Million TWD | 91.64% |
GeneFerm Biotechnology Co., Ltd. | 282.53 Million TWD | 73.069% |
Easywell Biomedicals, Inc. | 589.98 Million TWD | 87.103% |
TTY Biopharm Company Limited | 3.36 Billion TWD | 97.741% |
Synmosa Biopharma Corporation | 3.62 Billion TWD | 97.903% |
Orient EuroPharma Co., Ltd. | 6.64 Billion TWD | 98.856% |
Center Laboratories, Inc. | 6.78 Billion TWD | 98.879% |
Tien Liang BioTech Co., Ltd. | 161.05 Million TWD | 52.755% |
Orient Pharma Co., Ltd. | 892.18 Million TWD | 91.472% |
InnoPharmax Inc. | 48.64 Million TWD | -56.404% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | 320.99 Million TWD | 76.296% |
Excelsior Biopharma Inc. | 472.87 Million TWD | 83.909% |
DV Biomed Co., Ltd. | 765.87 Million TWD | 90.065% |
Foresee Pharmaceuticals Co., Ltd. | 616.93 Million TWD | 87.667% |
Handa Pharmaceuticals, Inc. | 280.88 Million TWD | 72.911% |
UniPharma Co., Ltd. | 37.4 Million TWD | -103.441% |
Anxo Pharmaceutical Co., Ltd. | 1.01 Billion TWD | 92.506% |
Winston Medical Supply Co., Ltd. | 373.87 Million TWD | 79.649% |
Mercury Biopharmaceutical Corporation | 49.72 Million TWD | -53.032% |
Bioray Biotech Co., Ltd | 108.75 Million TWD | 30.034% |
TSH Biopharm Corporation Limited | 133.62 Million TWD | 43.058% |